Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.70 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.61 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.58 |
| ▸ | ITGB2 | P05107 | 3/20 | 0.55 |
| ▸ | ICAM1 | P05362 | 3/20 | 0.55 |
| ▸ | ITGAL | P20701 | 3/20 | 0.55 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 3/20 | 0.52 |
| ▸ | CA2 | P00918 | 3/20 | 0.52 |
| ▸ | FAAH | O00519 | 2/20 | 0.51 |
| ▸ | CNR1 | P21554 | 2/20 | 0.51 |
| ▸ | CNR2 | P34972 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.50 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.47 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19051473 | 0.92 | SLC6A5 (0.63) | SLC6A5EPHX2SLC15A2ITGB2ICAM1 | |
| SCHEMBL9664616 | 0.90 | SLC6A5 (0.85) | SLC6A5EPHX2SLC15A2ITGB2ICAM1 | |
| SCHEMBL7257727 | 0.90 | SLC15A2 (0.69) | SLC6A5EPHX2SLC15A2ITGB2ICAM1 | |
| SCHEMBL9664374 | 0.89 | SLC6A5 (0.87) | SLC6A5EPHX2SLC15A2ITGB2ICAM1 | |
| SCHEMBL13279669 | 0.89 | SLC6A5 (0.87) | SLC6A5EPHX2SLC15A2ITGB2ICAM1 | |
| SCHEMBL15650015 | 0.89 | SLC6A5 (0.87) | SLC6A5EPHX2SLC15A2ITGB2ICAM1 | |
| SCHEMBL17817155 | 0.89 | SLC6A5 (0.87) | SLC6A5EPHX2SLC15A2ITGB2ICAM1 | |
| SCHEMBL22034112 | 0.89 | SLC6A5 (0.87) | SLC6A5EPHX2SLC15A2ITGB2ICAM1 | |
| SCHEMBL7887542 | 0.89 | SLC6A5 (0.69) | SLC6A5EPHX2SLC15A2ITGB2ICAM1 | |
| SCHEMBL4348859 | 0.89 | SLC6A5 (0.87) | SLC6A5EPHX2SLC15A2ITGB2ICAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170183318-A1 | AMIDE COMPOUNDS, METHODS FOR PREPARATION, AND USE THEREOF AS AGENTS FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY RNA- AND/OR DNA-CONTAINING VIRUSES, AND CONCOMITANT DISEASES | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU "PHARMENTERPRISES" (RU) | 2017-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170183318-A1 | AMIDE COMPOUNDS, METHODS FOR PREPARATION, AND USE THEREOF AS AGENTS FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY RNA- AND/OR DNA-CONTAINING VIRUSES, AND CONCOMITANT DISEASES | ACE, ACE2, MCTS1 | SLC6A5 3373/4885EPHX2 3269/4885SLC15A2 4413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.